Drugs.com - Pharma Industry News

ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM

FRIDAY, April 4, 2025 -- For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment...

Apr 4, 2025 - 19:11
 0
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
FRIDAY, April 4, 2025 -- For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment...
Read More

Tags:

Previous Article

The Gen3 Evo Cupra KIRO single-seater is unveiled at the Cupra City Garage in Ma...

Next Article

Greater Wealth Linked to Lower Mortality, With Stronger Link in U.S.

Related Posts

Adults in the United States Tend to Overstate Protective Value of Firearms

Adults in the United States Tend to Overstate Protectiv...

Feb 13, 2025  0

Sleep Time in First Week Postconcussion Linked to Youth Recovery Outcomes

Sleep Time in First Week Postconcussion Linked to Youth...

Mar 11, 2025  0

Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia

Acalabrutinib-Venetoclax Prolongs Survival in Previousl...

Feb 21, 2025  0